Nurturing Exercise Routine for Greater Improvement in Zest and Energy on Enhertu

Inclusion criteria

• Subject aged ≥ 18 years
• Diagnosis of locally advanced/unresectable or metastatic breast cancer. Note: Patients with High-Risk HER-2 + breast cancer after completion of neoadjuvant chemotherapy requiring adjuvant Enhertu are allowed at the discretion of the treating physician.
• Has received 3 or 4 cycles of Enhertu and is expected to continue treatment for at least 12 weeks. Note: HER-2 targeted systemic therapy (e.g. Trastuzumab and/or Pertuzumab) in conjunction with Enhertu is allowed.
• Able and willing to participate in the interventional aerobic exercise and resistance exercises.
• Currently following standard of care contraception requirements and willing to continue following these requirements for the duration of therapy.
• Able to provide informed consent and willing to sign an approved consent form that conforms to federal and institutional guidelines.
• Experiencing clinical fatigue symptoms in the opinion of the investigator.
• Subject has completed the ACSM exercise preparticipation health screening and is, in the opinion of the investigator, fit to participate in this study.

Exclusion criteria

• Currently adhering to national physical activity guidelines for resistance training, as defined as participating in structured resistance training ≥ two days per week.
• Structured is defined as time set aside in the subject's day to workout.
• Resistance training is defined as exercises which use weights, bands, or body weight (e.g., squats or push-ups).
• AND Currently participating in structured moderate-intensity aerobic exercise for ≥ 150 minutes per week.
• Moderate-intensity exercise is defined as activities where the subject can talk but not sing.
• Aerobic exercise includes, but is not limited to, walking, swimming, cycling, running, rowing, hiking, and elliptical.
• Medical, psychiatric, cognitive, or other conditions that may compromise the participant's ability to understand the participant information, give informed consent, comply with the study protocol or complete the study.
• Participants taking prohibited medications as described in Section 7.4.1.